SCHEMBL6702181

SCHEMBL6702181

NN=C1c2cc(S(=O)(=O)Nc3cccc(O)c3)ccc2-c2ccc(S(=O)(=O)Nc3cccc(O)c3)cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 3/20 0.58
UQCRB P14927 1/20 0.54
PKM P14618 2/20 0.52
KMT2A Q03164 3/20 0.51
STAT3 P40763 1/20 0.49
AURKB Q96GD4 5/20 0.47
KDR P35968 4/20 0.47
AURKA O14965 3/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47
PIM1 P11309 1/20 0.47
LTK P29376 1/20 0.47
MAPK14 Q16539 1/20 0.47
LRRK2 Q5S007 1/20 0.47
ALK Q9UM73 1/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 2/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6704050 0.89 AURKB (0.59) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6703746 0.86 AURKB (0.59) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6704528 0.86 AURKB (0.59) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6703748 0.86 AURKB (0.59) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6703763 0.86 STAT3 (0.65) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6701816 0.86 HSD17B2 (0.54) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6702771 0.85 HTR6 (0.54) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6702766 0.85 HTR6 (0.54) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6743069 0.84 HSD17B2 (0.52) HSD17B2UQCRBPKMKMT2ASTAT3
SCHEMBL6705029 0.83 STAT3 (0.69) HSD17B2UQCRBPKMKMT2ASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US claimed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US claimed
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US disclosed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS P2RX3, P2RX1, P2RX2 HSD17B2 2678/4885UQCRB 1293/4885PKM 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.